 NeoGenomics remains insulated and differentiated from peers via a plethora of offerings in clinical diagnostics, as a potential market-leader in oncology services. The growth vision looks at consolidating a myriad of oncology diagnostics under one roof via clinical and pharmaceutical services, both of which are meaningful compounders. 